# Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Source: https://onco.cc/trials/nct04229979/  
OnCo record `nct04229979` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Azacitidine, Venetoclax, Decitabine and Cytarabine in acute myeloid leukaemia, run by Sellas Life Sciences Group, active and no longer recruiting.

## Summary

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 is a phase 3 interventional study registered as NCT04229979 by Sellas Life Sciences Group, with 127 participants enrolled, started 2021-02-08 and due to reach its primary completion in 2025-12. Interventions recorded: Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine and GM-CSF.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04229979
- Phase: 3
- Setting: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
- Sponsor: Sellas Life Sciences Group
- Enrolled: 127

## Sources

- ClinicalTrials.gov NCT04229979: https://clinicaltrials.gov/study/NCT04229979

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Decitabine](https://onco.cc/drugs/decitabine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Galena Biopharma](https://onco.cc/companies/galena-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04229979.json